|
Non-Small Cell Lung Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> In summary, our data demonstrated that the USP9X-TTK axis may play a critical role in NSCLC, and could be considered as a potential therapeutic target.
|
29721084 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor cell expression of TTK and survivin proteins was confirmed using immunohistochemistry in an expanded patient cohort.
|
27918555 |
2017 |
|
Mucopolysaccharidoses
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mucopolysaccharidosis type 1 (MPS1) is an inherited lysosomal storage disorder caused by a deficiency in the glycosaminoglycan (GAG)-degrading enzyme α-l-iduronidase (IDUA).
|
28585336 |
2017 |
|
Mucopolysaccharidosis I
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Mucopolysaccharidosis I-Hurler (MPS I-H) is the most severe form of a metabolic genetic disease caused by mutations of IDUA gene encoding the lysosomal α-L-iduronidase enzyme.
|
28619065 |
2017 |
|
Valvular disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Valvular disease prevalence is similar to MPS I and II, but appears less severe.
|
29735373 |
2018 |
|
Fanconi Anemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Fanconi Anaemia-Like Mph1 Helicase Backs up Rad54 and Rad5 to Circumvent Replication Stress-Driven Chromosome Bridges.
|
30453647 |
2018 |
|
Mucopolysaccharidoses
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mucopolysaccharidosis type 1 (MPS-1), also known as Hurler's disease, is a congenital metabolic disorder caused by a mutation in the alpha-L-iduronidase (IDUA) gene, which results in the loss of lysosomal enzyme function for the degradation of glycosaminoglycans.
|
31065277 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
MPS-1 has been found to be increased in the sera of a number of different cancers, including head and neck squamous cell carcinoma (HNSCC).
|
19642098 |
2010 |
|
Mucopolysaccharidosis I
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
MPS I-H is the most severe form of alpha-l-iduronidase deficiency. alpha-l-iduronidase (encoded by the IDUA gene) is a lysosomal enzyme that participates in the degradation of dermatan sulfate and heparan sulfate.
|
19751987 |
2010 |
|
alpha-L-Iduronidase Deficiency
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
MPS I-H is the most severe form of alpha-l-iduronidase deficiency. alpha-l-iduronidase (encoded by the IDUA gene) is a lysosomal enzyme that participates in the degradation of dermatan sulfate and heparan sulfate.
|
19751987 |
2010 |
|
nervous system disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
MPS I-H is a rare, life-threatening disease, evolving in multisystem morbidity including progressive neurological disease, upper airway obstruction, skeletal deformity and cardiomyopathy.
|
28619065 |
2017 |
|
Cardiomyopathies
|
0.010 |
Biomarker
|
group |
BEFREE |
MPS I-H is a rare, life-threatening disease, evolving in multisystem morbidity including progressive neurological disease, upper airway obstruction, skeletal deformity and cardiomyopathy.
|
28619065 |
2017 |
|
Lung diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
TTK and other genetic loci identified in our study may contribute to the increased susceptibility to NTM infection and its progression to pulmonary disease.
|
28777004 |
2017 |
|
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
TTK has emerged as a promising therapeutic target in human cancers, including triple-negative breast cancer (TNBC).
|
29378962 |
2018 |
|
Triple-Negative Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
TTK has emerged as a promising therapeutic target in human cancers, including triple-negative breast cancer (TNBC).
|
29378962 |
2018 |
|
Mucopolysaccharidosis Type IIIA
|
0.080 |
Biomarker
|
disease |
BEFREE |
MPS I and II patients often develop cardiac involvement leading to early mortality, however there are limited data in MPS III.
|
29735373 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Mps1 is associated with the BRAF<sup>V600E</sup> mutation and predicts poor outcome in patients with colorectal cancer.
|
30854056 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MPS-1 was correlated with advanced tumor stage, suggesting its association with CRC progression.
|
31506433 |
2019 |
|
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
MPS-1 expression was positively associated with circulating leptin levels in CRC patients, especially in obese cases.
|
31506433 |
2019 |
|
Condyloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MPS-1 immunoreactivity was detected in the cytoplasm and/or the perinuclear regions of condylomata cells, with marked staining in areas of active proliferation.
|
8074479 |
1994 |
|
Hurler-Scheie Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A 13-year-old boy with Hurler-Scheie syndrome (MPS I-HS) presented with corneal clouding in both eyes.
|
30575621 |
2019 |
|
Clouding of corneal stroma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A 13-year-old boy with Hurler-Scheie syndrome (MPS I-HS) presented with corneal clouding in both eyes.
|
30575621 |
2019 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A novel USP9X substrate TTK contributes to tumorigenesis in non-small-cell lung cancer.
|
29721084 |
2018 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A previous study identified a novel gene, monopolar spindle protein kinase 1 (Mps1), a downstream target of BRAF<sup>V600E</sup> only, rather than of wild-type BRAF as well, which contributes to tumorigenesis in melanoma.
|
30854056 |
2019 |
|
melanoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
A previous study identified a novel gene, monopolar spindle protein kinase 1 (Mps1), a downstream target of BRAF<sup>V600E</sup> only, rather than of wild-type BRAF as well, which contributes to tumorigenesis in melanoma.
|
30854056 |
2019 |